RxDoctor Payments Data

Gregg Shander, MD

Clinical Cardiac Electrophysiology · Chattanooga, TNNPI 1497754733

Payments from drug & device makers

$1,432in general payments, 2019–2025

Across 34 payments — averaging $42.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biosense Webster, Inc.$727
  • Medtronic$221
  • Abbott$204
  • Novartis$92
  • Boston Scientific$76
  • Amarin Pharma, Inc.$48
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$1,432100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,432 in reported general payments places this provider in the 10th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

See all clinical cardiac electrophysiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$370,754
Medicare patients
1,552
Services billed
6,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban616$721,093
XareltoRivaroxaban94$120,414
EntrestoSacubitril/Valsartan45$57,530
Dofetilide60$22,015
Flecainide Acetate207$9,752
Dabigatran EtexilateDabigatran Etexilate Mesylate38$9,335
Amiodarone Hcl185$5,169
Mexiletine Hcl14$4,571
SotalolSotalol Hcl193$4,034
Metoprolol Succinate164$3,047
Metoprolol Tartrate325$2,076
Atorvastatin Calcium120$2,020
JantovenWarfarin Sodium311$2,001
Diltiazem 24hr Er (Cd)Diltiazem Hcl76$1,989
Propafenone Hcl28$1,914

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$721,093616 claims
NovartisEntresto$92$57,53045 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 82 clinical cardiac electrophysiology providers in Tennessee.

Other clinical cardiac electrophysiology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →